These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27555791)

  • 1. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.
    Hassoun AA; Pathan MF; Medlej RC; Alarouj M; Shaltout I; Chawla MS; Knap D; Vaz JA
    Diabetes Metab Syndr Obes; 2016; 9():225-31. PubMed ID: 27555791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
    Hassoun AA; Al-Arouj M; Ibrahim M
    Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study.
    Khattab M; Mahmoud K; Shaltout I
    Diabetes Ther; 2016 Sep; 7(3):551-60. PubMed ID: 27550549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
    Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
    Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
    Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
    J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan.
    Shete A; Shaikh A; Nayeem KJ; Rodrigues L; Ali MS; Shah P; Khanna R; Majid S; Rasheed SA; Shaikh S; Rahman T
    World J Diabetes; 2013 Dec; 4(6):358-64. PubMed ID: 24379927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan.
    Malha LP; Taan G; Zantout MS; Azar ST
    Ther Adv Endocrinol Metab; 2014 Feb; 5(1):3-9. PubMed ID: 24696775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
    Blüher M; Kurz I; Dannenmaier S; Dworak M
    World J Diabetes; 2012 Sep; 3(9):161-9. PubMed ID: 23125906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 15. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus.
    Panneerselvam P; Biswas D; Singh H; Dilip Kumar K; Ravi Kumar P; Kalra P; Revankar S; Warrier S
    Cureus; 2023 Oct; 15(10):e47190. PubMed ID: 38021574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.
    Halimi S; Levy M; Huet D; Quéré S; Dejager S
    Diabetes Ther; 2013 Dec; 4(2):385-98. PubMed ID: 23996548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.
    Göke R; Bader G; Dworak M
    Diabetes Ther; 2014 Jun; 5(1):183-91. PubMed ID: 24643724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management.
    Das S; Gupta AK; Bandyopadhyaya B; Darla BH; Arya V; Abhyankar M; Revankar S
    Bioinformation; 2021; 17(3):413-423. PubMed ID: 34092962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
    Forst T; Koch C; Dworak M
    Curr Med Res Opin; 2015 Jun; 31(6):1079-84. PubMed ID: 25867771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.